NICE Turn Down Bone Disorder Drug for NHS
As part of its highly specialised technologies programme, NICE have published draft guidance turning down Alexion Pharma’s Strensiq (asfotase alfa) which is used in the treatment for paediatric-onset hypophosphatasia.